Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma

Basel, 28 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the global launch of the VENTANA BAP1 (SP527)* test. This automated, ready-to-use immunohistochemistry (IHC) assay provides a reliable, highly specific diagnostic tool to help clinicians and pathologists accurately identify mesothelioma and distinguish it from other malignancies, including non-small cell lung cancer (NSCLC). The BAP1 assay is registered as a Class I IVD with U.S. Food and Drug Administration, has received IVDR approval as a Class C device, and is available globally.

GlobeNewsWire • Oct 28, 2026

Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors

Microsoft Corporation was the portfolio's top contributor during the quarter. Suncor Energy outperformed the Index during the quarter. KLA Corporation traded lower during the quarter.

Seeking Alpha • Oct 28, 2026

Roche: Valuation Leaves Limited Upside

Roche delivered 7% Q3 sales growth at constant currency, although approximately CHF 180 million was attributable to shipments that had been brought forward in Japan. Pharmaceuticals performed well, but Chinese pricing reforms continue to weigh on Diagnostics, while FX remains a headwind to reported earnings. Giredestrant and fenebrutinib offer future growth opportunities, although regulatory approvals and commercial performance remain important uncertainties.

Seeking Alpha • Oct 28, 2026

Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories

Basel, 27 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received the CE Mark for its cobas smart e immunoanalyser, a compact, standalone platform engineered to deliver reliable testing with a planned menu of over 100 high-medical-value assays.1,2 As the latest offering in Roche's industry-leading cobas immunoassay systems portfolio, the platform bridges critical operational gaps across health systems by fitting central-laboratory precision into a footprint under one square meter. This enables decentralised sites to manage diverse testing demands directly in-house. With reaction times of 18 minutes or less across more than 90% of Roche immunoassays, local facilities can help reduce diagnostic turnaround times.1,2

GlobeNewsWire • Oct 27, 2026

Roche says divarasib cut risk of death 44% in lung cancer trial

Swiss drugmaker Roche said on Sunday its experimental lung cancer drug divarasib reduced ​the risk of death by 44% compared ‌with existing treatments in a phase III study.

Reuters • Oct 25, 2026

Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

Basel, 25 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today pivotal results from the phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).

GlobeNewsWire • Oct 25, 2026

Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Divarasib demonstrated best-in-class efficacy in Phase III trial, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer.

Business Wire • Oct 25, 2026

Roche Targets Emerging Oncology Market With New Lung-Cancer Drug

The Swiss drugmaker expects a pill it is developing to become the new standard treatment for an advanced form of lung cancer, and the company's first shot at an emerging field within the oncology market.

WSJ • Oct 26, 2026

Roche Holding AG (RHHBY) Q3 2026 Sales/Trading Call Transcript

Roche Holding AG (RHHBY) Q3 2026 Sales/Trading Call Transcript

Seeking Alpha • Oct 23, 2026

Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

Basel, 23 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimised standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P

GlobeNewsWire • Oct 23, 2026